Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
6.65
+0.95 (16.67%)
Nov 18, 2026, 4:00 PM EST - Market closed
Akari Therapeutics, Employees
As of December 31, 2025, Akari Therapeutics, had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or 33.33% compared to the previous year. That makes Akari Therapeutics, the 41,285th largest employer in the world and 6,340th in the United States.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,900,500
Market Cap
15.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | -3 | -33.33% | 5 | 1 |
| Dec 31, 2024 | 9 | -3 | -25.00% | 8 | 1 |
| Dec 31, 2023 | 12 | -3 | -20.00% | 9 | 3 |
| Dec 31, 2022 | 15 | 6 | 66.67% | 15 | 0 |
| Dec 31, 2021 | 9 | 0 | - | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 113 |
| Fractyl Health | 100 |
| aTyr Pharma | 60 |
| Passage Bio | 24 |
| BioCardia | 21 |
| Quantum BioPharma | 17 |
| Tvardi Therapeutics | 12 |
| Actuate Therapeutics | 12 |
AKTX News
- 20 hours ago - Akari Therapeutics trading resumes - TheFly
- 21 hours ago - Akari Therapeutics trading halted, volatility trading pause - TheFly
- 6 days ago - Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform - GlobeNewsWire
- 7 days ago - Akari Therapeutics, Quarterly report: Q3 2026 - Filings
- 7 days ago - Akari Therapeutics, Earnings release: Q3 2026 - Filings
- 7 days ago - Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho - GlobeNewsWire
- 19 days ago - Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner - GlobeNewsWire